Penny Stocks Articles | Page 13 of 13

Progenics (NASDAQ:PGNX)

April 5, 2021 Travis Comments Off

Progenics (NASDAQ:PGNX)

Progenics (NASDAQ:PGNX) reported Q2 EPS and incomes in front of perspectives, and it was not because of superior to anything expected Relistor sovereignties. The organization perceived a $4 million point of reference installment from Bayer (OTCPK:BAYRY) for the PSMA Antibody Technology permit. This cooperation could open some shareholder esteem in the next years. News broke a week ago that Relistor is drawing some purchaser interest and that Valeant (NYSE:VRX) may offer its rights to the most noteworthy bidder.

A $400-500 million sticker price was specified in the Bloomberg article. The inferred cost allots little esteem to Relistor considering

Ocular Therapeutics Continues to Surge despite Headwinds

April 5, 2021 Travis Comments Off

Ocular Therapeutics Continues to Surge despite Headwinds

Ocular Therapeutics is up 34.8% recently subsequent to declaring that the FDA’s worries with respect to the organization’s New Drug Application (NDA) seem to have been tended to.

Situated in Bedford, MA, OCUL is a biopharmaceutical organization that spotlights on the improvement and commercialization of eye-consideration items. It has created DEXTENZA, a treatment intended to be directed for visual agony taking after eye-related surgery.

The FDA issued a Complete Response Letter (CRL) to the organization’s NDA, refering to worries about insufficiencies in OCUL’s assembling forms that were seen amid an assessment. However there

Neuralstem, Inc. (Nasdaq:CUR)

April 5, 2021 Travis Comments Off

Neuralstem, Inc. (Nasdaq:CUR)

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical organization concentrated on the advancement of focal sensory system treatments in light of its neural undifferentiated organism innovation, reported its money related results and gave business and clinical overhauls to the three and six months time spans finished June 30, 2016.

In the second quarter of 2016, the organization have taken measures to enhance the Company’s cost structure and finished activities to fortify the association, especially with the arrangement of another Scientific Policy Committee.

In Q2, the organization carried clinical headways with its lead compound, NSI-189, and they are satisfied with movement

Ligand Pharmaceuticals (NASDAQ:LGND)

April 5, 2021 Travis Comments Off

Ligand Pharmaceuticals (NASDAQ:LGND)

Financial specialists hoping to partake in the biotech space without going out on a limb related straightforwardly with medication advancement might need to investigate Ligand Pharmaceuticals (NASDAQ:LGND).

The organization depicts itself as a “biopharmaceutical” organization that is centered around creating or gaining advancements that help pharmaceutical organizations find and create drugs. They portray their income model as enhanced and their cost structure low and productive. Their objective for speculators is to offer a lower-hazard venture chance to take part in the guarantee of the biotech business.

Their operations concentrate on medication disclosure, early-arrange drug advancement, item transformation